Nuclera selected to join Bio-start's first cohort


Bio-start announced the 15 companies that will be joining the UK’s first synthetic biology accelerator programme. Applicants from across the UK have applied for entry into the 10-week intensive programme of high-quality mentorship, entrepreneurial training & workshops, with access to a global network of customers and opportunities. We are thrilled to be part of this exciting program, and look forward to meeting the other.

Nuclera joins the Stevenage BioScience Catalyst

01 / 11 / 2015

Nuclera have become virtual tenants at the Stevenage BioScience Catalyst, and will take up physical tenancy in January 2016. This move will place us at the centre of a world-leading life sciences cluster, acclerating our R&D through access to a wide-range of excellent facilities. Furthermore, the campus is an entrepreneurial hub for life sciences in the UK, so provides the ideal environment for Nuclera to grow and forge partnerships, both scientific and commercial, with other parties on the site.

Stevenage BioScience Catalyst is a joint venture between the Department for Business Innovation and Skills, GlaxoSmithKline, the Wellcome Trust and Innovate UK. They aim to give the next generation of pharma and biotech companies access to a spectrum of translation research and development activities and opportunities. This culture of open innovation will accelerate the discovery of cutting-edge healthcare solutions and place the UK bioscience sector at the forefront of worldwide biomedical innovation.